Pharmaceutical products place unusually high demands on packaging. A medicine pack is not simply a container or a branded carton. It forms part of a wider system involving product containment, identification, information, handling and safe use.
For businesses sourcing pharma packaging, this means structural design and print cannot be considered independently from the product’s regulatory and technical requirements. A folding carton for blister-packed tablets, for example, has a different role from the blister that directly contains the medicine.
In the UK, medicines packaging and labelling are regulated, and the Medicines and Healthcare products Regulatory Agency (MHRA) provides detailed guidance on the information and presentation expected for medicines. The agency emphasises clear identification and safe use, which makes legibility and information hierarchy practical safety considerations rather than purely aesthetic choices.
What Does Pharmaceutical Packaging Actually Include?
The phrase pharma packaging covers several packaging levels rather than one particular box, bottle or blister.
Primary packaging is the component that comes into direct contact with the dosage form. Depending on the medicine, this can include a blister, bottle, vial, ampoule, tube or another suitable container.
Secondary packaging does not directly contact the medicine. A printed carton containing a blister strip and patient leaflet is a familiar example. WHO terminology distinguishes primary packaging from secondary packaging on this direct-contact basis.
Transport packaging forms another layer and is used to support storage, handling and distribution rather than serving as the immediate patient-facing pack.
This distinction is important when discussing pharma packaging solutions. A printed pharmaceutical carton may form an essential part of the finished medicine presentation, but it should not be described as providing the same functional barrier as the primary container unless its specification actually supports that claim.
Why Secondary Pharma Packaging Has a Serious Job
Secondary cartons may appear structurally simple, but their design can carry a substantial information burden.
Medicine name, strength, pharmaceutical form and other required particulars may need to be communicated clearly. UK regulations set requirements for information appearing on outer and immediate packaging, including requirements concerning legibility, comprehensibility and permanence.
The carton may also need to accommodate a patient information leaflet and the primary container while remaining practical to pack, store and handle.
This changes the priorities of pharma packaging design.
Large decorative areas and elaborate visual effects should not interfere with mandatory information. Colour can help organise a product range, but visual similarity between different medicines or strengths can create risks if it makes packs difficult to distinguish.
The MHRA’s best-practice guidance specifically addresses clear medicine identification and the reduction of medication errors.
Designing a Pharmaceutical Carton Around Its Contents
Effective product packaging begins with accurate dimensions.
For a blister-based medicine, the designer needs the dimensions of the complete blister arrangement rather than only an individual tablet cavity. The number of strips, their orientation and the leaflet can all affect the internal carton size.
Bottled products create different considerations. The carton must accommodate the container and closure while allowing for any required leaflet or supporting components.
Unnecessary internal space can allow components to move and can increase the overall packaging footprint. A carton that is too tight may make assembly difficult or interfere with the contents.
Before structural artwork is finalised, it is useful to establish:
- dimensions of the complete primary pack;
- number and orientation of components;
- leaflet dimensions and folding method;
- required external information areas;
- closure and opening arrangement;
- packing-line considerations;
- storage and distribution requirements.
For bespoke packaging, these details should be resolved before visual design is treated as final.
Pharmaceutical Blister Packs and Outer Cartons
A pharmacy blister pack is one of the most recognisable medicine formats, but the blister and outer carton perform different jobs.
The blister is primary packaging when it directly contains the dosage form. The carton surrounding it is secondary packaging.
UK legislation specifically recognises blister packs placed inside compliant outer packaging and sets out information requirements for such immediate packaging.
This relationship affects carton design. A pack containing multiple blister strips must keep the components organised while providing appropriate space for required information and any leaflet.
A pharma pack should therefore be considered as a complete packaging system rather than as an isolated printed box.
For pharmaceutical businesses working with custom packaging suppliers, accurate information about the blister configuration is essential before a carton can be properly sized.
Clear Labelling Comes Before Decorative Design
Pharmaceutical printed packaging has a different information hierarchy from many ordinary retail products.
The primary objective is not simply to attract attention. Users and healthcare professionals need to identify the medicine and understand relevant information clearly.
Current MHRA guidance states that labels must be clear and that patients and healthcare professionals should be able to identify the medicine easily. It also addresses patient information leaflets, warnings and Braille requirements.
That makes typography, spacing and contrast important components of pharmaceutical packaging design.
A visually restrained carton can still carry strong brand recognition through consistent typography and controlled colour. Branded packaging does not need to dominate the information patients require.
Similarly, finishes should never be selected solely because they look premium. Any print, coating, embossing or other treatment needs to remain compatible with the approved artwork, readability requirements, production method and intended packaging use.
The UK-Only Requirement Needs Space in the Artwork
For pharma packaging UK, regulatory changes also affect artwork planning.
From 1 January 2025, medicines placed on the UK market must carry a clearly legible “UK Only” label under the arrangements associated with the Windsor Framework. MHRA guidance states that the wording may appear anywhere on the outer packaging but must be conspicuous and clearly legible.
This is a useful example of why pharmaceutical artwork cannot be designed as though regulatory content will simply be fitted into whatever space remains.
Required information should be mapped before decorative graphics are finalised.
Changes to legislation, authorisation particulars or product information can also create artwork revisions. Packaging systems therefore benefit from layouts that are structured and controlled rather than unnecessarily complicated.
Patient Information Leaflets Are Part of the Pack
A pharmaceutical carton may also need to accommodate a patient information leaflet.
MHRA guidance states that medicines must include a PIL when the label does not contain all the necessary information, and the agency reviews aspects such as font, colours, text size and layout for accessibility and readability.
From a structural perspective, the leaflet occupies real space.
Its folded thickness needs to be considered alongside the primary container. Ignoring it during initial sizing can produce a carton that works in a digital drawing but becomes difficult to close or pack during production.
For custom printed packaging, this is another reason structural sampling should precede a larger order.
A physical sample can help confirm whether the intended blister, bottle or other component and leaflet fit the carton as planned. It does not, however, replace regulatory review, compatibility testing or other pharmaceutical quality requirements.
Child-Resistant Packaging Is Product-Specific
The phrase “child-resistant” should never be applied casually to pharmaceutical packaging.
UK requirements apply to specified medicines and container systems. MHRA guidance states that packaging for certain medicines containing aspirin, paracetamol or more than 24 mg of elemental iron must be child-resistant, subject to specified exceptions. It also references recognised standards for reclosable and non-reclosable child-resistant packaging.
Importantly, changing parts of a packaging system can affect its child-resistant performance. The MHRA identifies factors including changes to blister material, foil, adhesive, pocket orientation and closure components.
A standard folding carton should therefore not be marketed as child-resistant merely because it encloses medicine.
Where child-resistant performance is required, the complete relevant packaging system must meet the applicable requirements.
Pharmaceutical Packaging Suppliers Need an Accurate Brief
A useful relationship with pharmaceutical packaging suppliers starts with a detailed specification.
Simply requesting “medicine boxes” does not communicate enough information for responsible packaging development.
The brief may need to cover carton dimensions, board specification, print requirements, structural style, primary pack dimensions, leaflet allowance and approved artwork requirements.
Businesses comparing packaging UK options should also distinguish between a packaging printer’s role and the responsibilities of the medicine manufacturer or marketing authorisation holder.
The packaging supplier may manufacture a carton to an agreed specification, but this does not automatically mean that the supplier determines whether the complete medicinal product packaging complies with every applicable pharmaceutical requirement.
Responsibilities should be understood and documented rather than assumed.
Designing for a Range of Medicines
A pharmaceutical company may need cartons for several strengths, formulations or pack sizes within one product family.
Consistency is useful for brand recognition, but excessive similarity can make variants harder to distinguish.
The MHRA’s guidance highlights the potential for confusion caused by similarities in medicine names and packaging.
A well-planned pharma packaging design system therefore needs both consistency and differentiation.
Typography can remain consistent while strength information receives clear prominence. Colour may assist differentiation, but it should not be the only distinguishing feature because users may encounter packs in different lighting conditions or have colour-vision limitations.
For bespoke packaging solutions, the objective should be a repeatable design system that gives every SKU enough individual clarity.
Packaging Changes Need Careful Control
Pharmaceutical packaging is not a format where artwork should be casually altered between print runs.
A small change in dimensions, text placement, material or packaging component can have wider implications.
The Human Medicines Regulations set requirements for information on medicinal product packaging, while MHRA guidance explains expectations around packaging and labelling.
This makes version control particularly important.
Approved artwork files, specifications and revisions need to be managed carefully so that outdated versions are not accidentally treated as current.
For custom printed packaging, pre-production checking should include more than visual appearance. Text accuracy, positioning, readability, dimensions and the correct artwork version all matter.
What About Sustainable Pharma Packaging?
Environmental considerations are increasingly discussed across packaging, but pharmaceutical requirements introduce important limitations.
Reducing unnecessary material can be worthwhile, yet changes cannot compromise product requirements, approved specifications or patient information.
A lighter carton, alternative material or smaller format should therefore be evaluated within the requirements of the complete pharmaceutical product rather than being labelled automatically as a more sustainable solution.
Claims also need evidence.
Terms such as recyclable, biodegradable or environmentally friendly should not be applied to a pharma pack without understanding its complete materials, coatings, components and relevant disposal or recycling arrangements.
Practical material efficiency and accurate environmental communication are more useful than broad unsupported claims.
Where Custom Packaging Pro UK Fits
Custom Packaging Pro UK provides custom packaging options for businesses, including printed carton formats that may be considered for pharmaceutical and healthcare product presentation.
For pharmaceutical projects, however, bespoke packaging UK should always be developed against the specific product brief and applicable requirements. A visually suitable carton does not by itself establish regulatory compliance, compatibility with a medicine or suitability for direct pharmaceutical contact.
Businesses should therefore provide accurate specifications and ensure that appropriate regulatory, technical and quality checks are completed by the responsible parties.
Pharmapack Europe and the Wider Packaging Industry
Searches for pharmaceutical packaging sometimes lead to Pharmapack Europe, which is different from the general term pharma pack.
Pharmapack is a European industry event focused on pharmaceutical packaging, drug delivery, medical devices and machinery. The official event site states that Pharmapack Europe 2027 is scheduled for 27–28 January 2027 at Paris Expo Porte de Versailles, Hall 4, Paris, France.
This distinction matters for search intent. Someone looking for Pharmapack 2027 or Pharma Pack Paris is generally seeking information about the industry event, whereas someone searching for pharma packaging solutions is more likely to be researching packaging formats, suppliers or design requirements.
Final Thoughts
Good pharma packaging requires more discipline than simply placing pharmaceutical branding onto a box.
Primary packaging, secondary cartons, patient information, structural fit and regulatory labelling each have distinct roles. For UK medicines, current MHRA requirements and the Human Medicines Regulations need to be considered alongside the technical specification of the individual product.
For businesses sourcing pharma packaging solutions, the practical starting point is a complete specification: know what the carton contains, what information it must accommodate, how it will be packed and which requirements apply before artwork is finalised.
That approach gives designers, pharmaceutical businesses and packaging suppliers a clearer foundation for developing custom printed packaging that is organised, readable and appropriate for its intended role.
FAQs
- What kind of company is Pharmapack?
Pharmapack in this context is an industry event rather than a pharmaceutical packaging manufacturer. The official Pharmapack Europe site describes it as a European event for pharmaceutical packaging, drug delivery, medical devices and machinery.
- When and where will Pharmapack Europe 2027 be held?
Pharmapack Europe 2027 is scheduled for 27 and 28 January 2027 at Paris Expo Porte de Versailles, Hall 4, in Paris, France.
- What is pharmaceutical packing?
Pharmaceutical packing covers the operations and packaging components used to contain, present and prepare a pharmaceutical product as a finished pack. WHO terminology distinguishes primary materials that contact the product from secondary packaging that does not directly contact it.
- What are the main types of pharmaceutical packaging?
A useful distinction is between primary, secondary and transport packaging. Primary packaging directly contacts the medicine, secondary packaging can include the patient-facing carton around the primary pack, and transport packaging supports distribution.
- What information is required on pharmaceutical packaging in the UK?
Requirements depend on the medicine and packaging level. UK legislation specifies information for outer and immediate packaging, while MHRA guidance covers areas including medicine identification, warnings, patient information and presentation. The exact requirements should be checked for the specific medicinal product.
- Do medicines in the UK need “UK Only” on the packaging?
Medicinal products placed on the UK market are subject to the “UK Only” labelling arrangements introduced from 1 January 2025. MHRA guidance specifies that the wording must be clearly legible and conspicuous on the outer packaging.
- Are pharmaceutical blister packs child-resistant?
Not automatically. Child-resistant requirements depend on the medicine and packaging system. Where they apply, relevant reclosable or non-reclosable packaging must meet the applicable standards identified in UK guidance.
- Who are the “big 3” in pharma?
There is no single official “big three” because rankings vary according to the measure used, such as revenue, market capitalisation, prescription-drug sales or geographic market. For packaging procurement, company-size rankings are generally less relevant than the specific medicine, regulatory requirements and packaging specification.
